THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

The Role of Targeted HIV Screening in the Emergency Department

Citation for published version:

Spagnolello, O, Gallagher, B, Lone, N, Ceccarelli, G, D'Ettorre, G & Reed, MJ 2020, 'The Role of Targeted HIV Screening in the Emergency Department: A Scoping Review', *Current HIV Research: HIV and Viral Immune Diseases*. <https://doi.org/10.2174/1570162X18666201123113905>

Digital Object Identifier (DOI):

[10.2174/1570162X18666201123113905](https://doi.org/10.2174/1570162X18666201123113905)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Current HIV Research: HIV and Viral Immune Diseases

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

THE ROLE OF TARGETED HIV SCREENING IN THE EMERGENCY DEPARTMENT: A SCOPING REVIEW

Ornella Spagnolello *¹, Bernadette Gallagher², Nazir Lone ^{3,4} (0000-0003-2707-2779), Giancarlo Ceccarelli ¹ (0000-0001-5921-3180), Gabriella D'Ettorre ¹ (0000-0002-3571-5677), Matthew J Reed ^{2,4} (0000-0003-1308-4824)

¹ Department of Public Health and Infectious Diseases, University of Rome Sapienza, Rome, Italy

² Emergency Medicine Research Group Edinburgh (EMERGE), Department of Emergency Medicine, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh, EH16 4SA, UK.

³ Department of Critical Care, Royal Infirmary of Edinburgh, Little France Crescent, Edinburgh, EH16 4SA, UK.

⁴ Usher Institute, University of Edinburgh, NINE, 9 Little France Road, Edinburgh BioQuarter, Edinburgh, EH16 4UX

Review article: 7234 words, 1 Figure, 2 Tables, 2 Appendix, 100 references

Key words: HIV, targeted screening, emergency department, public health, early diagnosis, low-prevalence areas

Running title: Targeted HIV testing in the ED

* Corresponding Author

Address for correspondence:

Department of Public Health and Infectious Diseases, University of Rome Sapienza, Rome, Italy

Tel: +39 3339900344

ORCID ID: 0000-0002-6201-389X

E-mail address: spagnolello.ornella@gmail.com

CONTRIBUTIONS: All authors were involved in the conception of the study, study design, analysis and interpretation of data and drafting the article. OS collected the data.

COMPETING INTERESTS: The authors declare no conflict of interest, financial or otherwise.

STUDY FUNDING: The authors have no funding to declare.

PATIENT CONSENT FOR PUBLICATION: Not required for the purpose of a scoping review.

ETHICS APPROVAL: Not required for the purpose of a scoping review.

The Role of Targeted HIV Screening in the Emergency Department: A Scoping Review

ABSTRACT

Background. Human immunodeficiency virus (HIV) infection continues to expand worldwide and a significant proportion of infection is still undiagnosed. Recent studies have addressed the impact and feasibility of '*opt-out*' HIV screening in Emergency Departments (EDs) in urban settings at high HIV prevalence, whereas little is known about the yield of implementing '*targeted*' HIV testing especially in low-prevalence areas.

Objective. The present study undertakes a scoping review of research carried out on the implementation of targeted HIV screening in adult EDs to determine the impact, feasibility and acceptability of HIV testing in different HIV prevalence settings.

Design. Online databases (EMBASE, MEDLINE) were used to identify papers published between 2000 to 2020. A three-concept search was employed with HIV (HIV, Human immunodeficiency virus infection, HIV infections), targeted testing (Target, screening or testing) and emergency medicine (Emergency Service, emergency ward, A&E, accident and emergency or Emergency Department) (28th February 2020). Only full-text articles written in English, French, Spanish or Italian and using impact and/or feasibility and/or acceptability of the program as primary or secondary outcomes were analysed.

Results. The search returned 416 articles. Of these, 12 met inclusion criteria and were included in the final review. Most of the included studies were carried out in the United States ($n=8$; 67%) and in areas of high HIV prevalence ($n=11$; 92%). Three (20%) were randomized control studies. While the rate of newly diagnosed HIV cases varied widely (0.03-2.2%), likely due to methodological heterogeneity between studies, the linkage of new HIV diagnosis was often high (80-100%) and median CD4+ cell count was always greater than 200 cells per microliter. Targeted HIV screening was found to be cost-effective (out of 2 studies) and well accepted by participants (out 2 studies).

Conclusions. Targeted HIV screening at the ED can be impactful, feasible and well accepted, but often requires extra funding and staff. Most previous work has focused on areas of high disease prevalence.

INTRODUCTION

Considerable steps forward have been achieved in terms of Human Immunodeficiency Virus (HIV) knowledge and antiretroviral therapy (ART) over the last 30 years. Despite this, the overall number of People Living with HIV (PLHIV) is still rising [1]. All the more alarming, is the statistic from the European Centre for Disease Prevention and Control (ECDC) 2017 report that up to one quarter of PLHIV are unaware of their HIV status [2].

As part of the international effort to globally counteract the Acquired Immune Deficiency Syndrome (AIDS) epidemic, the United Nations HIV/AIDS (UNAIDS) Program has set the ambitious *90-90-90 targets* by 2020: 90% of all people with HIV diagnosed, 90% of those diagnosed to be on antiretroviral treatment, and 90% of those on treatment being virally suppressed [3]. Wider access to HIV testing remains therefore a challenge to urgently overcome.

Delayed HIV diagnosis increases the risk of severe complications and premature mortality [4,5,6,7,8,9,10,11], as well as the chance of virus transmission [12,13,14], ultimately leading to major resource usage and healthcare cost [15,16,17,18,19,20]. Therefore, a systematic HIV screening program could be of benefit not only to the patient but also to the whole community. HIV testing is becoming increasingly prevalent as part of routine in-hospital investigations for certain group of patients, such as those electively undergoing surgery or pregnant women during prenatal care [21,22,23,24,25,26,27,28,29,30,31,32]. However, those interventions selectively target only a limited group of patients that have access to specific health care facilities.

It is well accepted that the ED can offer a strategic point of testing for a number of healthcare conditions [33,34,35,36,37,38,39,40,41,42,43,44,45]. In the UK, similar to many European countries, almost a quarter of the country's population attend an ED every year making it a sensible place to introduce an HIV testing program [46,47]. Moreover, the ED offers 24/7 assistance to marginalized and traditionally underserved populations (e.g. migrant people, homeless, intravenous drugs users) in whom HIV is known to be more prevalent [48,49,50,51,52].

Two main approaches to delivery of screening are suggested by HIV testing guidelines: (1) a universal screening strategy aiming to test people aged 13 to 64 years in all clinical settings unless the patient declines ("*opt-out*" screening), or (2) a targeted strategy in which the test is offered to individuals presenting with indicator conditions [53,54,55] Although the universal "*opt-out*" screening is by far the best strategy to detect HIV early in the asymptomatic stage of the infection,

it has been shown to be cost-effective only in populations with an HIV prevalence greater than 0.1% [56].

In light of recommendations issued by national and international agencies (*Centre of Disease Control and Prevention*; CDC, the ECDC, the *British HIV association*; BHIVA and the *National Institute for Health and Care Excellence*; NICE), routine non-targeted HIV screening has been adopted in some EDs located in areas of high-HIV prevalence [2,57,58,59]. However, currently EDs are overstretched and the dedicated funding to support universal testing is not widely available. On the other hand, no clear recommendation has been issued so far regarding targeted HIV screening and evidence about its ED implementation is sparse. Identifying the most effective approaches to screening will allow better implementation and more evidence of the yield of screening in areas at lower HIV prevalence is still required.

The main objective of this scoping review is to investigate the impact, feasibility and acceptability of a systematic targeted HIV testing program at the ED, especially in areas at low HIV prevalence.

METHODS

The final protocol was registered on Open Science Framework on 6th February 2020 (<https://osf.io/ajyec/>) and is available on request from the corresponding author.

To be included in the review, papers needed to focus on targeted HIV screening in the ED. A three-concept search including HIV (HIV, Human immunodeficiency virus infection, HIV infections), targeted testing (Target, screening or testing) and emergency medicine (Emergency Service, emergency ward, A&E, accident and emergency or Emergency Department) was initially run without any restrictions and two (O.S., B.G. – 28th February 2020) authors screened each result.

Peer-reviewed journal papers were included if they were:

- published between 2000-2020
- written in English, French, Spain or Italian
- full-text articles
- ED-centered, or where ED data could be extracted

- involving adults (aged > 16 years)
- including outcomes of impact and/or feasibility and/or acceptability [Table 1]

Papers were excluded if they were:

- centered on “non-targeted” or “opt-out” HIV screening strategy
- limited to specific setting (e.g.. veterans)
- descriptive case series, survey, review, study protocol, serosurvey, comparison among laboratory techniques

In order to identify potentially relevant documents, the bibliographic databases MEDLINE and EMBASE were searched from 2000-2020. Grey literature was hand-searched through Google Scholar, conference proceedings, ClinicalTrial.gov and OpenGrey for unpublished research. The search strategies were drafted by an experienced librarian [M.D.] and further refined through team discussion. The final search strategy for MEDLINE and EMBASE can be found in **Appendix 1**. The final search results were exported into EndNote, and duplicates were removed by a library technician.

Two reviewers independently evaluated the titles, abstracts and then full text of all publications identified by our initial search for potentially relevant publications. We resolved disagreements on study selection and data extraction by consensus and discussion with other reviewers if needed.

A data-charting form was jointly developed by two reviewers to determine which variable to extract [Table 2]. The two reviewers independently charted the data, discussed the results and continuously updated the data-charting form in an iterative process.

Data from eligible studies were charted using a standardized data extraction tool designed for this study. The tool captured the relevant information on key study characteristics and detailed information on all metrics used to estimate previously listed outcomes anywhere in the article. Any disagreements were resolved through discussion between the two reviewers or further adjudication by a third party if necessary.

We abstracted data on article characteristics (country of origin, study population and sample size), methodology/methods (study design, type of test, funding/staff model, aims/purpose, outcome measure) and key results.

We grouped the studies by predefined outcomes investigated (impact, feasibility and acceptability) [Table 1] and summarized the study designs for each group, along with the measures used and broad findings [Table 2].

High HIV prevalence was defined as local authorities with a diagnosed HIV prevalence of between 2 and 5 per 1000 people aged 15 to 59 years (NICE 2016). High patient volume ED was defined as receiving over 50,000 patients annually or covering an urban area of more than 600,000 inhabitants. Study funding was classified as government funding, commercial funding and non-profit foundations (e.g. charities).

RESULTS

After duplicates were removed, a total of 241 citations were identified from searches of electronic databases and review article references. Based on the title and the abstract, 167 were excluded, with 44 full-text articles to be retrieved and assessed for eligibility. Of these, 32 were excluded for the following reasons:

- Study design did not fit with eligibility criteria ($n=9$)
- Only abstract for conference ($n=16$)
- Review – data already extrapolated ($n=2$)
- Review – data could not be extrapolated ($n=2$)
- Limited to specific setting ($n=2$)
- Out of study search study time span ($n=1$)

The remaining 12 studies were considered eligible for this review [Figure 1]. The list of excluded papers with reason can be found in Appendix 2.

Studies' characteristics, methodology and key results are presented in Table 2.

All papers were published between 2005 and 2019. Most of the included studies were carried out in the United States ($n=8$; 67%)[60,61,63,64,65,66,67] and in area at high HIV prevalence (2 and 5

per 1000 people tested; > 0.20%) ($n=11$; 92%) [60,61,62,64,65,66,67,68,69]. 6 studies were performed in EDs receiving a high volume of patients (defined as over 50,000 patients annually or covering urban area of more than 600,000 inhabitants) [62,63,64,66,69].

The study period varied from 4 months to 6 years.

In terms of study design, 25% ($n=3$) included studies that were randomized controlled trials (RCT) [62,64,68]. Of these, one was a randomized cross-over design study, one a cluster-randomized trial (CRT) comparing targeted vs non-targeted HIV screening and one a 2-period cluster-randomized crossover trial (CRXO) comparing targeted HIV screening vs diagnostic testing. 3 (25%) were prospective studies: two evaluating targeted HIV screening vs diagnostic testing and one comparing targeted HIV screening to non-targeted HIV screening [60,66]. The remaining papers included were retrospective studies ($n=4$; 33%) [61,63,65], a cost-utility study ($n=1$) [67] and a post-analysis study ($n=1$) [69].

Two different methods of HIV testing were adopted: rapid bedside HIV assessment ($n=8$; 67%), conventional ELISA with confirmatory Western blot ($n=3$; 25%) or both ($n=1$; 8%).

Although all studies were government funded, two were also supported by commercial funding. In 5 studies (42%) the HIV screening was entirely run by ED staff including physicians, nurses, nurse practitioners and social workers.

The majority of studies ($n=8$; 67%) primarily focused on measures of impact of targeted HIV screening, whereas one entirely addressed patient acceptability and one was centered on program feasibility. Of the two remaining studies, one equally included measures of impact and feasibility while the other was focused on both impact and acceptability.

The main findings of the studies are discussed below.

Impact

The rate of newly diagnosed HIV cases was the most investigated measure of impact among included studies. This figure varied widely from 0.03 to 2.2%, mainly due to heterogeneity in methodology and definitions. In the two studies reporting the highest rate of new HIV diagnoses, the number of new diagnoses was compared to the number of patients tested and not to the total population included [60,61]. In both studies the number of patients refusing the test was not reported. In contrast, the study with the lowest rate of newly diagnosed HIV cases (0.03%) was a 2-

period CRXO carried out in France where the number of new HIV diagnoses was compared to a denominator made up all patients approached [62]. Comparing the number of new HIV diagnoses to a denominator made up only of patients who were tested led to an increase in the prevalence of newly diagnosed HIV cases to 0.7%. In the only study carried out in a low prevalence area (0.16%), the rate of new HIV diagnoses was 0.7%, therefore still comparable to the above study performed in a high prevalence setting [63]. The rate of new HIV diagnosis, defined as new cases divided by patients tested, was greater in low compared with high volume EDs (low volume ED: 1.2, 1.4, 2.2, 2.2 vs high volume ED: 0.7, 0.22, 0.7, 1.3).

Another measure of impact taken into account by many studies was the linkage to care, defined as the proportion of patients with new HIV diagnosis attending follow-up care at the infectious disease center. This value was often high, between 80 and 100%. The only exception was the targeted arm of the CRT carried out in US by Lyons MS et al (2013) where only two of three new HIV diagnosis were successfully linked to care [64].

CD4+ cell count was reported in only two studies focused on impact of targeted HIV screening. In the retrospective study led by Christopoulos KA (United States 2011) the median CD4+ cell count at diagnosis was 268 cells per microliter [65]. During the targeted period of the prospective study carried out by Haukoos JS (United States 2013) the median CD4+ cell count was 244 cells per microliter (vs 272 during the non-targeted period) [66].

Feasibility

Two studies addressed economic analysis of targeted HIV screening. Dowdy DW et al. performed a cost-utility analysis of a screening program entirely supported by ED staff over 4 months in an urban ED in San Francisco (United States 2011): largely because of its benefit in preventing HIV transmission, for every patient tested, targeted screening was shown to save 112 US Dollars [67]. In contrast, according to the results of the CRXO carried out by Leblanc J et al. in multiple EDs in Paris (DICI-VIH study - France 2018), the incremental cost per additional new diagnosis was 1324 Euros [62].

Acceptability

Two European studies were focused on patient acceptability of HIV targeted screening in the ED. In the RCT performed by Gillet C. et al (Switzerland 2018), patient acceptance in the targeted arm was 48% and was not significantly different when compared to the non-targeted arm [68]. In a post-analysis of the DICI-VIH study, Leblanc J. et al. showed how patient acceptance varied from 64 to 77% across EDs, increasing with research staff involvement and decreasing over time (France 2019) [69].

DISCUSSION

Our scoping review shows that targeted HIV screening at the ED has proved to be impactful, feasible and well accepted in the ED population, but may require increased staffing resource and extra funding. Despite being tested in high-HIV prevalence setting in most of the cases, targeted screening might be appropriate also in low prevalence areas.

Although the majority of studies in this scoping review were from the US between 2005 and 2013, those based in Europe (France, Spain and Switzerland) were more recent (2018-2019).

Study design varied between prospective and retrospective studies, with one third of evidence arising from RCTs. Despite most of the studies included addressing measures of impact, the rate of new HIV diagnosis was not easily comparable given methodological variability. In this regard, retrospective studies may over-estimate this outcome normalizing new HIV diagnosis to the number of patients tested, and not to the total approached. Interestingly, the only study carried out in a low HIV prevalence area reported a rate of new HIV diagnosis still comparable to other studies performed in a high prevalence setting [63]. The volume of patients may also play a role on measures of impact with low volume EDs showing a higher rate of new HIV diagnosis. This can be easily explained by the evidence that when ED becomes overstretched, especially in a staff-limited setting, clinical activities take over research/screening projects [70,71,72,73].

The high burden of HIV infection worldwide and the large proportion of PLHIV unaware of their serostatus means that early HIV detection represents a crucial public health challenge [1,74,75]. This is especially true given ART availability, its effectiveness in reducing viral load and its beneficial

effects in term of survival rate and morbidity particularly at this stage of the infection [76,77]. Moreover, it is well recognized that early HIV identification may have a role in prevention of virus transmission from index cases to uninfected people [76,77,78,79]. HIV screening is therefore key not only for successful treatment but also for infection prevention. Therefore, many international and national agencies (CDC, BHIVA, the NICE and ECDC) have been supporting the deployment of effective public health measures in this regard. Although HIV testing has been traditionally offered in limited health care settings (e.g. Sexual Health clinics) [80,81], it has been expanded in non-traditional settings in the attempt to make it more accessible, ED being one of these areas. Indeed, it is well recognised that the ED might play a crucial role in HIV screening since it treats patients who may not normally use the health system and may be at increased risk of infection [48]. Moreover, routine blood samples are likely to be part of ED clinical care and can be easily used for testing [82].

On the grounds of these considerations, “*opt-out*” HIV screening at the ED was firstly introduced in the US as part of routine medical care for all patients aged 13-64 years in areas with HIV prevalence greater than 0.1% (CDC 2006) [57]. However, evidence of success and long-term sustainability were debatable. Similarly, despite the endorsement of the ECDC for universal screening in settings at high HIV prevalence (2017), the situation across Europe is quite diverse [2]. In the UK, BHIVA (2008) and NICE (2016) published guidelines for HIV testing in all patients attending the ED in high (2-5/1000) and very high (5 or over/1000) risk areas [58,59]. London was the first city in the UK to offer non-targeted HIV screening in the ED, given that the overall prevalence of HIV in London is 5.4/1000 (England 1.9/1000) [83]. Reports of these experiences showed that non-targeted testing was feasible and well accepted by staff and patients and did not adversely affect length of ED stay when offered to patients having routine blood tests [84,85,86,87,88,89,90,91,92]. However, non-targeted screening requires many tests and may include patients previously known to have a HIV positive status. Concerns therefore persist about its feasibility and effectiveness in the long run especially in setting at lower HIV prevalence [93,94,95,96,97,98]. On the other hand, testing selectively increases the likelihood of new HIV diagnoses whilst running fewer tests, but requires actively selecting patients to be offered the test increasing the workload and thought process for busy ED staff.

The results of our scoping review show that the interest in targeted HIV screening at the ED is now moving from the US to Europe, with the latest studies being carried out in France, Spain and Switzerland. Although there is a growing body of evidence around the implementation of targeted HIV screening in European EDs, there is no published UK experience, thus far.

The gap between national recommendations and ED test implementation in the real-world points towards two main challenges to overcome: The need for extra staff and for supplementary funding (equipment, laboratory services etc).

Despite studies comparing targeted vs non-targeted testing showing that targeted testing may lead to fewer tests being performed, and hence being cheaper on the number of assays being performed, additional testing (rather than blanket non-targeted testing) in the ED requires extra staff time [64,68]. Schrantz SJ (2011) and Leblanc J (2019) found that testing frequency decreased over time after introduction when screening was carried out by ED staff [61,69]. Moreover, the post hoc analysis of the DICI-VIH study shows that questionnaire distribution was higher on weekdays and when research staff were available but decreased over time and when demand on the ED increased [69]. This is in line with the results of our scoping review where low volume EDs showed a higher rate of new HIV diagnosis. Therefore if this is to be introduced outside the scope of a well-resourced research study, thought is required as to how this extra workload on staff would be managed, and who would be best placed to perform it to keep the screening program running effectively in the long run and to sustain good practice. The key aspect of screening is patient selection and questionnaire distribution which is problematic in an environment such as the ED. On the other hand, it was found that this role might be able to be fulfilled also by well-trained non-health workers. For example, in the RCT carried out by Gillet, C et al., patient selection and questionnaire distribution was entirely conducted by an appropriately trained medical student [68].

The results of our scoping review should be interpreted in light of several limitations. First of all, only one study was found that was carried out in a low HIV prevalence setting, therefore our findings may not be generalizable in areas of lower prevalence.

Secondly, it should be considered that given differences in health care systems, data from the US might not be comparable to Europe and that different targeted HIV screening protocols may differ in selection criteria.

Finally, all of our included studies were performed as part of well-resourced research studies. There may be many EDs across Europe and the rest of the world that have implemented HIV testing (either targeted or non-targeted) and have not reported the findings of their practice.

CONCLUSIONS

Targeted HIV screening at the ED can be impactful, feasible and well accepted among ED encounters, but its long-term implementation requires extra funding and supplemental staff limiting its application in low resources setting.

More studies carried out in areas of low HIV prevalence are warranted. Moreover, more data coming from low and middle-income countries are needed.

ACKNOWLEDGEMENTS: The authors would like to thank M.D. for her professional support at this scoping review as expert librarian.

Table and Figure legends:

Figure 1: Study flow chart

Table 1: Predefined outcomes of impact, feasibility and acceptability

Table 2: Summary of articles

Figure 1: Selection of included studies

Table 1

IMPACT	Rate of new HIV cases Rate of “early” HIV diagnosis Linkage to care of patients with newly Diagnosed HIV
FEASIBILITY	Staff compliance Cost/efficacy overview
ACCEPTABILITY	Patient test acceptance

Table 2

Author(s), (<i>journal</i> and year of publication)	Country of origin, [HIV- prevalence] [§]	Sample size, [study period]	Study design	Type of test(s)	Funding, Staffing model	Aims/Purpose	Outcome measures	Key findings
Gillet, C. (<i>PLoS ONE</i> 2018) [68]	Switzerland, [0.20-0.50%], Low volume ED [°]	n=160 [4-month]	RCT* (targeted vs non-targeted HIV test)	Rapid	Government funding, Supplemental staff [^]	1. Test the use of electronic tablets to offer testing 2. Examine whether non-targeted screening increased testing rate	HIV testing rate	a. Testing rate was lower in targeted vs non-targeted arm (10 vs 48%) b. Acceptance rate did not differ between targeted vs non-targeted arm (48 vs 53%)
Leblanc, J. DICI-VIH study (<i>Ann Emerg Med</i> 2018) [62]	France, [0.20-0.50%], High volume ED ^{°°°}	n=148.327 [1-year]	2-period CRXO** (targeted test vs control strategy) Multi-centers	Rapid	Government/Commercial funding, Supplemental staff [^]	1. Compare effectiveness of nurse-driven targeted HIV screening to standard practice	1. Proportion of new HIV diagnosis 2. Intervention's incremental cost per additional diagnosis	a. Proportion of new HIV diagnosis was higher in targeted test vs standard practice (3.0/10.000 vs 0.8/10.000) (0.03%) (0.7%) b. The incremental cost was 1.324 EU per additional new diagnosis
						2. Compare cost- effectiveness of the two strategies		
Leblanc, J. DICI-VIH study (<i>Worldviews Evid Based Nurs</i> 2019) [69]	France, [0.20-0.50%], High volume ED ^{°°°}	n=148.327 [1-year]	Post-analysis	Rapid	Government/Commercial funding, Supplemental staff [^]	Investigate factors associated with the implementation of targeted HIV screening	1. Proportion of questionnaires distributed 2. Proportion of testes accepted	a. Questionnaire distribution proportions were higher on weekdays and when research staff participated. They decreased over time and with increased ED volume. b. Patient acceptance increased with research staff participation and decreased over time.

Gomez-Ayerbe, C. DRIVE study (<i>PLoS One</i> 2019) [99]	Spain, [0.35%] ^{§§} , Low volume ED°	n=1631 [3-year]	Prospective evaluation study (targeted HIV test vs standard practice)	Rapid	Government funding, Supplemental staff	Evaluate the impact of targeted HIV screening program in comparison to standard practice	1. n° of newly diagnosed HIV patients 2. Testing coverage	Rate of newly diagnosed HIV patients and testing coverage was significantly higher in the targeted HIV testing program than in clinical practice (14/1000 vs 6/1000) (1.4%)
Lyons, M. S. (<i>J Acquir Immune Defic Syndr</i> 2013) [64]	United States, [0.36%] ^{§§} , High volume ED°°	n=9.572 [2-year]	CRT*** (targeted vs non-targeted HIV test)	ELISA, Rapid	Government/Commercial funding, Supplemental staff	Compare n° of new HIV diagnosis among the two strategies	1. Proportion of new HIV diagnosis 2. Proportion of eligible/approachable patients tested; acceptance rate; risk profile of tested patients; notification rate; n° of newly diagnosed patients linked to care; reasons for declining testing; initial CD4 count in newly diagnosed patients	a. Proportion of new HIV diagnosis was only slightly lower in targeted vs non-targeted arm (0.22% vs 0.31%) b. Testing rate was remarkably higher in non-targeted vs targeted arm (40.7% vs 29.7%) c. Targeted arm: 66% linkage to care
Dowdy, D. W. (<i>Acad Emerg Med</i> 2011) [67]	United States, [0.20-0.50%], Low-volume ED°	n=3.766 [4-month]	Cost-utility analysis	Rapid	Government funding, ED staff	Evaluate cost-effectiveness of a previously implemented targeted HIV screening program	1. Cost of the program 2. n° of QALYs**** gained; n° of estimated HIV transmission events prevented	a. Per patient tested, targeted screening saved 112 Dollars and resulted in 2.71 QALYs gained b. Targeted test prevented an estimated 2.1 HIV transmission events over 16 months
Hudepohl, N. J. (<i>Ann Emerg Med</i> 2011) [100]	United States, [0.20%], High volume ED°°	n=11.503 [6-year]	Retrospective observational study	ELISA	Government funding, Supplemental staff	Evaluate the cumulative effect over time of a previously implemented	1. Proportion of patients tested who reported a previous test/had a previous test within the program	Targeted HIV testing program can have relevant cumulative effects over time since a sizeable proportion of patients returns to the ED more

						targeted screening program	2. The cumulative proportion of patients tested in the program	than once (2.6% visits provided with test; 6.9% patients tested)
Haukoos, J. S. (<i>Acad Emerg Med</i> 2007) [60]	United States, [0.20-0.50%], Low volume ED°	n=681 [30-month]	Prospective cohort study	Rapid	Government funding, ED staff	Test a physician-based targeted HIV model	1. Characterize patients identified by the model 2. Proportion of patients completing counseling, testing and referral 3. n° of newly diagnosed HIV patients and proportion of these linked to care	Only 0.64% of patients transiting ED were evaluated and completed counseling, testing and referral. Of these, 15 patients tested positive (2.2%) and 12 (80%) were successfully linked to care.
Lyons, M. S. (<i>Ann Emerg Med</i> 2005) [63]	United States, [0.16%], High volume ED°°	n=8574 [4-year]	Retrospective observational study	ELISA	Government funding, Supplemental staff	Evaluate the degree to which a targeted HIV screening program can be successful in a low-prevalence setting	n° of newly diagnosed HIV patients	a. 0.7% of patients approached tested positive b. To implement a targeted HIV screening program in a low-prevalence setting is possible, but requires greater resources than in high-prevalence area
Schrantz, S. J. (<i>Ann Emerg Med</i> 2011) [61]	United States, [0.20-0.50%], Low volume ED°	n=1258 [13-month]	Retrospective observational study	ELISA	Government funding, ED staff	Describe the implementation of a local targeted HIV screening program	1. n° of patients approached, n° of patients tested, n° of newly diagnosed HIV patients linked to care 2. Factor prompting patient selection, changes in testing frequency	1.2% of the total ED visitors were tested. Of these, 2.2% resulted in a new HIV diagnosis, of whom 89% were linked to care. Targeted test might lead to increasing testing even in absence of special resources allocated.

								However, testing frequency decreases with the time.
Haukoos, J. S. (<i>Ann Emerg Med</i> 2013) [66]	United States, [0.20-0.50%], High volume ED ^{oo}	n=58016 [8-month]	Prospective before-after design	Rapid	Government funding, ED staff	Compare targeted HIV screening using Denver HIV Risk Score to non-targeted HIV testing	<p>1. n° of newly diagnosed HIV patients</p> <p>2. Total HIV diagnosis, CD4 cell count, viral load, successful linkage to care</p>	<p>Targeted HIV testing with Denver HIV Risk Score was strongly associated with new HIV diagnosis when compared to non-targeted screening (1.3% vs 0.2%).</p> <p>The proportion of patients tested into the targeted strategy was only 1/7 of the non-targeted one.</p> <p>Median CD4 cell count was 244 per microliter and 272 per microliter (targeted vs non-targeted).</p> <p>100% of linkage to care.</p>
Christopoulos, K. A. (<i>AIDS Patient Care STDS</i> 2011) [65]	United States, [0.20-0.50%], Low- volume ED ^o	n=5340 [17-month]	Retrospective observational study	Rapid	Government funding, ED staff ^{^^}	Evaluate the impact of adding targeted HIV screening to diagnostic testing	<p>1. n° of patients tested, n° of newly diagnosed HIV patients, n° of newly diagnosed HIV patients linked to care</p> <p>2. Demographics and CD4 cell count</p>	<p>Median number of tests per month and new HIV diagnosis per month significantly increased after the change in testing strategy.</p> <p>1.2% of patients tested resulted HIV positive. Of these, over 90% were successfully linked to care.</p> <p>Median CD4 cell count 268 per microliter.</p>

§Local HIV-prevalence was tested or estimated

§§Hospital seroprevalence

°ED receiving less than 50.000 patients annually or covering urban area of more less than 600,000 inhabitants

°°50,000 patients annually or covering urban area of more than 600,000 inhabitants

°°°8 EDs in serving the 20% of adult local population

^research nurses, medical students

^^ with supplementary program coordinator

RCT* = randomized controlled study

CRXO** = cluster-randomized crossover trial

CRT*** = cluster-randomized trial

QALYS**** = quality-adjusted life years

Appendix 1 – Search Strategy

MEDLINE Search Strategy (Literature Search performed: 28th Feb 2020):

1. exp HIV infections/ (649450)
2. HIV.mp. (748838)
3. (Target*adj4 (screen* or test*)).mp. (53912)
4. exp Emergency Service, Hospital/ (79814)
5. (A&E or “accident and emergency” or Emergency Department*).mp. (1497590)
6. 1 or 2 (910758)
7. 4 or 5 (1535274)
8. 3 and 6 and 7 (205)

EMBASE Search Strategy (Literature Search performed: 28th Feb 2020):

1. exp Human immunodeficiency virus infection/ (371171)
2. HIV.mp. (748838)
3. (Target*adj4 (screen* or test*)).mp. (53912)
4. emergency ward/ (205262)
5. (A&E or “accident and emergency” or Emergency Department*).mp. (1497590)
6. 1 or 2 (869295)
7. 4 or 5 (1571405)
8. 3 and 6 and 7 (209)

Appendix 2 - List of excluded papers with reason

Targeting HIV testing at a population level: Cost effectiveness of three approaches Ayerbe, C. G.	Study design did not fit with eligibility criteria
Comparison of routine versus targeted HIV testing strategies: Coverage and estimated missed infections in emergency room and primary care centre Elias, M. J. P.	Study design did not fit with eligibility criteria
Cost-effectiveness analysis of universal vs targeted human immunodeficiency virus (HIV) screening approaches to identify new HIV diagnoses in the emergency department (ED) Batista, A. E.	Only abstract for conference
Yield of screening in the ED: Effectiveness versus efficacy Derks, L. S.	Only abstract for conference
HIV risk assessment using longitudinal electronic health records Feller, D.	Only abstract for conference
Incremental cost per newly diagnosed HIV infection (NDHI): Routine (RTS), targeted (TTS), and current clinical practice testing strategies (CPTS) Gomez-Ayerbe, C.	Only abstract for conference
A multi-center pragmatic randomized comparison of HIV screening strategy effectiveness in the emergency department: The HIV tested trial Haukoos, J.	Only abstract for conference
A pragmatic randomized clinical trial of rapid HIV screening in emergency departments Haukoos, J.	Only abstract for conference
Enhanced targeted HIV screening using the denver HIV risk score outperforms nontargeted screening in the emergency department Haukoos, J.	Only abstract for conference
Clinical staff satisfaction of and barriers to targeted and nontargeted opt-out HIV screening in the emergency department: Results from "the HIV tested trial" Haukoos, J.	Only abstract for conference
Effect of rapid HIV screening on emergency departments operational processes and patient throughput: Results from the HIV tested pragmatic randomized effectiveness trial Haukoos, J.	Only abstract for conference
Targeted bedside emergency department HIV screening does not impact length of stay Hernandez, B.	Only abstract for conference
All current emergency department screening strategies for human immunodeficiency virus still leaving many patients undiagnosed	Only abstract for conference

Hsieh, Y. H.	
HIV testing practices and provider attitudes in belize emergency care Wiskel, T.	Only abstract for conference
Screening for HIV: Systematic review to update the 2005 U.S. Preventive Services Task Force recommendation Chou, R.	Review – data already extrapolated
Understanding patient acceptance and refusal of HIV testing in the emergency department Christopoulos, K. A.	Study design did not fit with eligibility criteria
Bundled HIV and Hepatitis C Testing in the Emergency Department: A Randomized Controlled Trial Cowan, E.	Study design did not fit with eligibility criteria
Derivation and validation of the Denver Human Immunodeficiency Virus (HIV) risk score for targeted HIV screening Haukoos, J.	Study design did not fit with eligibility criteria
Risk-based human immunodeficiency virus (HIV) testing fails to detect the majority of HIV-infected persons in medical care Settings Jenkins, T. C.	Study design did not fit with eligibility criteria
Acceptability of HIV Testing Sites Among Rural and Urban African Americans Who Use Cocaine Keith Branham, D.	Limited to specific setting
Missed opportunities for concurrent HIV-STD testing in an academic emergency department Klein, P. W.	Limited to specific setting
The impact of nurse-driven targeted HIV screening in 8 emergency departments: study protocol for the DICI-VIH cluster-randomized two-period crossover trial Leblanc, L. J.	Study design did not fit with eligibility criteria
Effectiveness of nurse-driven HIV screening targeting key populations in emergency departments in metropolitan Paris: The anrs dici-vih cluster-randomized two-period crossover trial Leblanc, L. J.	Only abstract for conference
Relationship of self-reported prior testing history to undiagnosed HIV positivity and HIV risk Lyons, M. S	Study design did not fit with eligibility criteria
Rapid HIV Screening in the Emergency Department Torres, M.	Review – data already extrapolated
Rapid point-of-care HIV testing in youth: A systematic review Turner, S. D.	Review – data could not be extrapolated
Risk, reasons for refusal, and impact of counseling on consent among ED patients declining HIV screening Ubhayakar N.D.	Study design did not fit with eligibility criteria

Rates of emergency department human immunodeficiency virus (HIV) tested in patients tested for sexually transmitted diseases Waxman, M.	Only abstract for conference Limited to specific setting
Influence of an emergency department laboratory order set on rates of HIV and syphilis screening among patients tested for gonorrhea and chlamydia White, D. A. E	Only abstract for conference Limited to specific setting
Missed opportunities for targeted HIV screening and diagnosis among emergency department patients tested for sexually transmitted infections White, D. A. E.	Only abstract for conference Limited to specific setting
HIV screening programs in US emergency departments: a cross-site comparison of structure, process, and outcomes Torres, G. W.	Review – data could not be extrapolated
Feasibility of an emergency department-based, risk-targeted voluntary HIV screening program Kelen, G. D.	Out of study search study time span

REFERENCES

- ¹ Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS data 2018
- ² European Centre for Disease Prevention and Control. Thematic report: continuum of HIV care. Monitoring implementation of the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia: 2017 progress report. Stockholm: ECDC; 2017
- ³ 90-90-90: AN AMBITIOUS TREATMENT TARGET TO HELP END THE AIDS EPIDEMIC. UNAIDS. Available at <https://www.unaids.org/en/resources/909090>
- ⁴ Rodger AJ, Sabin CA. How have guidelines on when to start antiretroviral therapy affected survival of people living with HIV infection? *Curr Opin HIV AIDS* 2016;11:487–91
- ⁵ Sobrino-Vegas P, García-San Miguel L, Caro-Murillo AM, Miró JM, Viciano P, Tural C, Saumoy M, Santos I, Sola J, del Amo J, Moreno S; CoRIS. Delayed diagnosis of HIV infection in a multicenter cohort: prevalence, risk factors, response to HAART and impact on mortality. *Curr HIV Res.* 2009 Mar;7(2):224-30. doi: 10.2174/157016209787581535. PMID: 19275591.
- ⁶ Teira Cobo R, Suárez Lozano I, Santamaría Jáuregui JM, Terrón Pernía A, Domingo Pedrol P, González García J, Cosín Ochaíta J, Ribera Pascuet E, Sánchez T, Roca Villanueva B, Viciano Fernández P, García Alcalde ML, Geijo Martínez P, Galindo Puerto P, Vergara Campos A, Lozano de León Naranjo F, Muñoz Sánchez A, Tebas P. Diagnóstico tardío de la infección por el virus de la inmunodeficiencia humana en la Cohorte VACH (1997-2002) [Delayed diagnosis of HIV infection in the Spanish VACH cohort [1997-2002]]. *Gac Sanit.* 2007 Jan-Feb;21(1):66-9. Spanish. doi: 10.1157/13099123. PMID: 17306189.
- ⁷ Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. *N Engl J Med* 2009; 360:1815– 1826.
- ⁸ May MT, Vehreschild JJ, Trickey A, et al. Mortality according to CD4 count at start of combination antiretroviral therapy among HIV-infected patients followed for up to 15 years after start of treatment: collaborative cohort study. *Clin Infect Dis* 2016; 62:1571 – 1577.
- ⁹ Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. *Lancet Infect Dis* 2014; 14:281 – 290.
- ¹⁰ TEMPRANO ANRS 12136 Study Group. Danel C, Moh R, et al. Trial of early antiretrovirals and isoniazid preventive therapy in Africa. *N Engl J Med* 2015; 373:808 – 822.
- ¹¹ INSIGHT START Study Group. Lundgren JD, Babiker AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. *N Engl J Med* 2015; 373:795 – 807.
- ¹² Miller WC, Powers KA, Smith MK, et al. Community viral load as a measure for assessment of HIV treatment as prevention. *Lancet Infect Dis* 2013;13:459–64
- ¹³ Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Cottle L, Zhang XC, Makhema J, Mills LA, Panchia R, Faesen S, Eron J, Gallant J, Havlir D, Swindells S, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano DD, Essex M, Hudelson SE, Redd AD, Fleming TR; HPTN 052 Study Team. Antiretroviral

-
- Therapy for the Prevention of HIV-1 Transmission. *N Engl J Med*. 2016 Sep 1;375(9):830-9. doi: 10.1056/NEJMoa1600693. Epub 2016 Jul 18. PMID: 27424812; PMCID: PMC5049503.
- ¹⁴ Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med*. 2011 Aug 11;365(6):493-505. doi: 10.1056/NEJMoa1105243. Epub 2011 Jul 18. PMID: 21767103; PMCID: PMC3200068.
- ¹⁵ Krentz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present late (CD4<200 cells/microL) with HIV infection. *HIV Med*. 2004; 5:93–98
- ¹⁶ Martínez Colubi M, Pe´rez Eli´as MJ, Muriel A. Delayed diagnosis of HIV Infection: Prevalence, risk factors and high costs. Belgrade, Serbia: 13th European AIDS Conference/EACS; 2011; 12–15
- ¹⁷ Guillon M, Celse M, Geoffard PY. Economic and public health consequences of delayed access to medical care for migrants living with HIV in France. *Eur J Health Econ*. 2018 Apr;19(3):327-340. doi: 10.1007/s10198-017-0886-6. Epub 2017 Mar 25. PMID: 28343331.
- ¹⁸ Nosyk B, Lima V, Colley G, Yip B, Hogg RS, Montaner JS. Costs of health resource utilization among HIV-positive individuals in British Columbia, Canada: results from a population-level study. *Pharmacoeconomics*. 2015 Mar;33(3):243-53. doi: 10.1007/s40273-014-0229-8. PMID: 25404425; PMCID: PMC4677778.
- ¹⁹ Fleishman JA, Yehia BR, Moore RD, Gebo KA; HIV Research Network. The economic burden of late entry into medical care for patients with HIV infection. *Med Care*. 2010 Dec;48(12):1071-9. doi: 10.1097/MLR.0b013e3181f81c4a. PMID: 21063228; PMCID: PMC3022268.
- ²⁰ Levy A, Johnston K, Annemans L, Tramarin A, Montaner J. The impact of disease stage on direct medical costs of HIV management: a review of the international literature. *Pharmacoeconomics*. 2010;28 Suppl 1:35-47. doi: 10.2165/11587430-000000000-00000. PMID: 21182342.
- ²¹ David R McGowan, Joseph M Norris, Matthew D Smith, Meher Lad. Routine testing for HIV in patients undergoing elective surgery. *The Lancet*. September 15, 2012 DOI:[https://doi.org/10.1016/S0140-6736\(12\)61537-2](https://doi.org/10.1016/S0140-6736(12)61537-2)
- ²² K Chapman, J Meadows, J Catalan, B Gazzard. Testing patients for HIV before surgery: the views of doctors performing surgery. *AIDS Care*. 1995;7(2):125-8. doi: 10.1080/09540129550126632.
- ²³ Fournier AM, Zeppa R. Preoperative screening for HIV infection. A balanced view for the practicing surgeon. *Arch Surg*. 1989 Sep;124(9):1038-40. doi: 10.1001/archsurg.1989.01410090044009. PMID: 2774903.
- ²⁴ Manjul Mohan, Mohit Sharma, C.P. Pandey, Ajay Mohan Agarwal. Preoperative Screening of HIV, HBV, HCV Essential for Surgical Team and Patients both - A Research Study in Department of Surgery, Tertiary Care Institute of North India, Rohilkhand Medical College and Hospital, Bareilly (U.P.) India. *International Journal of Contemporary Medical Research*. ISSN (Online): 2393-915X; (Print): 2454-7379
- ²⁵ W. J. Harrison. HIV/AIDS in trauma and orthopaedic surgery. *The Journal of Bone and Joint Surgery*. British volume Vol. 87-B, No. 9. <https://doi.org/10.1302/0301-620X.87B9.16543>

-
- ²⁶ Lisa Keenan-Lindsay, Mark H. Yudin. HIV Screening in Pregnancy. *Journal of Obstetrics and Gynaecology Canada*. Volume 28, Issue 12, December 2006, Pages 1103-1107. [https://doi.org/10.1016/S1701-2163\(16\)32327-1](https://doi.org/10.1016/S1701-2163(16)32327-1)
- ²⁷ M J Postma, E J Beck, S Mandalia et al. Universal HIV screening of pregnant women in England: cost effectiveness analysis. *BMJ* 1999;318:1656
- ²⁸ Op de Coul, E.L., Hahné, S., van Weert, Y.W. et al. Antenatal screening for HIV, hepatitis B and syphilis in the Netherlands is effective. *BMC Infect Dis* 11, 185 (2011). <https://doi.org/10.1186/1471-2334-11-185>
- ²⁹ Jeffrey L. Ecker. The cost-effectiveness of human immunodeficiency virus screening in pregnancy. *American Journal of Obstetrics and Gynecology*. Volume 174, Issue 2, February 1996, Pages 716-721. [https://doi.org/10.1016/S0002-9378\(96\)70455-6](https://doi.org/10.1016/S0002-9378(96)70455-6)
- ³⁰ Bristow CC, Larson E, Anderson LJ, Klausner JD. Cost-effectiveness of HIV and syphilis antenatal screening: a modelling study. *Sex Transm Infect*. 2016 Aug;92(5):340-6. doi: 10.1136/sextrans-2015-052367. Epub 2016 Feb 26. PMID: 26920867; PMCID: PMC4956558.
- ³¹ Giraudon I, Forde J, Maguire H, Arnold J, Permalloo N. Antenatal screening and prevalence of infection: surveillance in London, 2000-2007. *Euro Surveill*. 2009 Mar 5;14(9):8-12. PMID: 19317973.
- ³² Chou R, Cantor AG, Zakher B, Bougatsos C. Screening for HIV in pregnant women: systematic review to update the 2005 U.S. Preventive Services Task Force recommendation. *Ann Intern Med*. 2012 Nov 20;157(10):719-28. doi: 10.7326/0003-4819-157-10-201211200-00009. PMID: 23165663.
- ³³ Ahmad I, Ali PA, Rehman S, Talpur A, Dhingra K. Intimate partner violence screening in emergency department: a rapid review of the literature. *J Clin Nurs*. 2017 Nov;26(21-22):3271-3285. doi: 10.1111/jocn.13706. Epub 2017 Mar 22. PMID: 28029719.
- ³⁴ Boudreaux ED, Camargo CA Jr, Arias SA, Sullivan AF, Allen MH, Goldstein AB, Manton AP, Espinola JA, Miller IW. Improving Suicide Risk Screening and Detection in the Emergency Department. *Am J Prev Med*. 2016 Apr;50(4):445-453. doi: 10.1016/j.amepre.2015.09.029. Epub 2015 Dec 4. PMID: 26654691; PMCID: PMC4801719.
- ³⁵ Hawk K, D'Onofrio G. Emergency department screening and interventions for substance use disorders. *Addict Sci Clin Pract*. 2018 Aug 6;13(1):18. doi: 10.1186/s13722-018-0117-1. Erratum in: *Addict Sci Clin Pract*. 2019 Jul 16;14(1):26. PMID: 30078375; PMCID: PMC6077851.
- ³⁶ Langerman SD, Badolato GM, Rucker A, Jarvis L, Patel SJ, Goyal MK. Acceptability of Adolescent Social and Behavioral Health Screening in the Emergency Department. *J Adolesc Health*. 2019 Oct;65(4):543-548. doi: 10.1016/j.jadohealth.2019.05.019. Epub 2019 Jul 31. PMID: 31377163; PMCID: PMC6764595.
- ³⁷ Teeuw AH, Kraan RBJ, van Rijn RR, Bossuyt PMM, Heymans HSA. Screening for child abuse using a checklist and physical examinations in the emergency department led to the detection of more cases. *Acta Paediatr*. 2019 Feb;108(2):300-313. doi: 10.1111/apa.14495. Epub 2018 Aug 14. PMID: 29992712.
- ³⁸ Jenkins WD. Chlamydia and gonorrhea screening in the emergency department setting: increasing evidence of utility and need for further research. *Am J Emerg Med*. 2019 Jun;37(6):1196. doi: 10.1016/j.ajem.2018.10.033. Epub 2018 Oct 18. PMID: 30355478.
- ³⁹ White DA, Anderson ES, Pfeil SK, Deering LJ, Todorovic T, Trivedi TK. Hepatitis C Virus Screening and Emergency Department Length of Stay. *PLoS One*. 2016 Oct 19;11(10):e0164831. doi: 10.1371/journal.pone.0164831. PMID: 27760176; PMCID: PMC5070782.

-
- ⁴⁰ Adler D, Abar B, Wood N, Bonham A. An Intervention to Increase Uptake of Cervical Cancer Screening Among Emergency Department Patients: Results of a Randomized Pilot Study. *J Emerg Med*. 2019 Dec;57(6):836-843. doi: 10.1016/j.jemermed.2019.07.021. Epub 2019 Oct 5. PMID: 31594738; PMCID: PMC6904518.
- ⁴¹ Fallon A, Kilbane L, Briggs R, Dyer A, Nabeel S, McElwaine P, Collins R, Coughlan T, O'Neill D, Ryan D, Kennelly SP. Screening for frailty in older emergency department patients: the utility of the Survey of Health, Ageing and Retirement in Europe Frailty Instrument. *QJM*. 2018 Mar 1;111(3):151-154. doi: 10.1093/qjmed/hcx242. PMID: 29237068.
- ⁴² Kaltiso SO, Greenbaum VJ, Agarwal M, McCracken C, Zmitrovich A, Harper E, Simon HK. Evaluation of a Screening Tool for Child Sex Trafficking Among Patients With High-Risk Chief Complaints in a Pediatric Emergency Department. *Acad Emerg Med*. 2018 Nov;25(11):1193-1203. doi: 10.1111/acem.13497. Epub 2018 Oct 31. PMID: 30381877.
- ⁴³ Brock C, Yi Y, Papaluca T, Lucas B, Angus PW, Taylor D, Leung C. Exploring the feasibility of targeted chronic hepatitis B screening in the emergency department: A pilot study. *Emerg Med Australas*. 2018 Dec;30(6):864-866. doi: 10.1111/1742-6723.13118. Epub 2018 Jun 9. PMID: 29885209.
- ⁴⁴ Lappin JM, Ayub MH, Rogers D, Morgan M, Kanyamibwa JY, Shakeshaft A. Routine screening and related interventions significantly improve the effectiveness of emergency department detection and management of alcohol withdrawal syndrome. *Emerg Med Australas*. 2018 Oct;30(5):648-653. doi: 10.1111/1742-6723.12959. Epub 2018 Mar 12. PMID: 29529713.
- ⁴⁵ Scott RL, Cummings GE, Newburn-Cook C. The feasibility and effectiveness of emergency department based hypertension screening: a systematic review. *J Am Acad Nurse Pract*. 2011 Sep;23(9):493-500. doi: 10.1111/j.1745-7599.2011.00636.x. Epub 2011 Jun 13. PMID: 21899644.
- ⁴⁶ NHS: London Health Programmes. Quality and Safety Programme Emergency departments: Case for change (http://www.londonhp.nhs.uk/wp-content/uploads/2013/03/ED-Case-for-change_FINAL-Feb2013.pdf)
- ⁴⁷ Minassian A, Vilke GM and Wilson MP (2013) Frequent emergency department visits are more prevalent in psychiatric, alcohol abuse, and dual diagnosis conditions than in chronic viral illnesses such as hepatitis and human immunodeficiency virus. *Journal of Emergency Medicine* 45, 520–525
- ⁴⁸ Wu L, et al. (2012) Alcohol and drug Use disorders among adults in emergency department settings in the United States. *Annals of Emergency Medicine*. 60, 172–180.e5
- ⁴⁹ Leaman AM, Rysdale E, Webber R. Use of the emergency department by Polish migrant workers. *Emerg Med J*. 2006 Dec;23(12):918-9. doi: 10.1136/emj.2006.035980. PMID: 17130598; PMCID: PMC2564252.
- ⁵⁰ Grimm JW, Wells JL. Illegal immigrants in the emergency department: an ethical dilemma for nurses? *J Emerg Nurs*. 2009 Apr;35(2):127-8. doi: 10.1016/j.jen.2008.08.018. Epub 2008 Oct 17. PMID: 19285176.
- ⁵¹ Salhi BA, White MH, Pitts SR, Wright DW. Homelessness and Emergency Medicine: A Review of the Literature. *Acad Emerg Med*. 2018 May;25(5):577-593. doi: 10.1111/acem.13358. Epub 2018 Jan 11. PMID: 29223132.
- ⁵² Nambiar D, Spelman T, Stoové M, Dietze P. Are People Who Inject Drugs Frequent Users of Emergency Department Services? A Cohort Study (2008-2013). *Subst Use Misuse*. 2018 Feb 23;53(3):457-465. doi: 10.1080/10826084.2017.1341921. Epub 2017 Oct 16. PMID: 29035611.
- ⁵³ US Preventive Services Task Force. Screening for HIV: Recommendation Statement. *Am Family Phys*. 2014; 89:666AD
- ⁵⁴ Go`kengin D, Geretti AM, Begovac J, Palfreeman A, Stevanovic M, Tarasenko O, et al. 2014 European Guideline on HIV testing. *Int J STD AIDS*. 2014; 25:695–704

-
- ⁵⁵ HIV in Europe Initiative. HIV Indicator Conditions: Guidance for Implementing HIV Testing in Adults in Health Care Settings. Copenhagen, Copenhagen University, 2015
- ⁵⁶ Hayes R, Sabapathy K, Fidler S. Universal testing and treatment as an HIV prevention strategy: research questions and methods. *Curr HIV Res*. 2011; 9:429–445
- ⁵⁷ Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. *MMWR*. 2006; 55:RR-14.
- ⁵⁸ British HIV Association (BHIVA). UK National Guidelines for HIV Testing 2008. BHIVA; 2008
- ⁵⁹ National Institute for Health and Care Excellence (NICE). HIV testing: increasing uptake among people who may have undiagnosed HIV. NICE; 2016
- ⁶⁰ Haukoos JS, Hopkins E, Eliopoulos VT, Byyny RL, Laperriere KA, Mendoza MX, *et al*. Development and implementation of a model to improve identification of patients infected with HIV using diagnostic rapid testing in the emergency department. *Acad Emerg Med* 2007; 14:1149–1157.
- ⁶¹ Schrantz, S. J., Babcock, C. A., Theodosis, C., Brown, S., Mercer, S., Pillow, M. T., *et al*. A targeted, conventional assay, emergency department HIV testing program integrated with existing clinical procedures. *Ann. Emerg. Med* 2011; 58, S85–S88e81.
- ⁶² Leblanc J, Hejblum G, Costagliola D, *et al*.; for the DICI-VIH Group. Targeted HIV screening in eight emergency departments: the DICI-VIH cluster randomized two-period crossover trial. *Ann Emerg Med* 2018; 10.1016/j.annemergmed.2017.09.011
- ⁶³ Lyons MS, Lindsell CJ, Ledyard HK, Frame PT, Trott AT, Emergency department HIV testing and counseling: an ongoing experience in a low-prevalence area, *Ann Emerg Med*, 2005, vol. 46 1 (pg. 22-28)
- ⁶⁴ Lyons MS, Lindsell CJ, Ruffner AH *et al*. Randomized comparison of universal and targeted HIV screening in the emergency department. *J Acquir Immune Defic Syndr* 2013;64:315–23
- ⁶⁵ Christopoulos KA, Kaplan B, Dowdy D, *et al*. Testing and linkage to care outcomes for a clinician-initiated rapid HIV testing program in an urban emergency department. *AIDS patient care and STDs*. 2011 Jul;25(7):439–444.
- ⁶⁶ Haukoos JS, Hopkins E, Bender B, Sasson C, Al-Tayyib AA, Thrun MW. Comparison of Enhanced Targeted Rapid HIV Screening Using the Denver HIV Risk Score to Nontargeted Rapid HIV Screening in the Emergency Department. *Ann Emerg Med*. 2013 Jan 3
- ⁶⁷ Dowdy DW, Rodriguez RM, Bradley Hare C, Kaplan B. Cost-effectiveness of targeted human immunodeficiency virus screening in an urban emergency department. *Acad Emerg Med*. 2011;18(7):745–53.
- ⁶⁸ Gillet C, Darling KE, Senn N, Cavassini M, Hugli O. Targeted versus non-targeted HIV testing offered via electronic questionnaire in a Swiss emergency department: a randomized controlled study. *PLoS One*. 2018;13(3):e0190767.
- ⁶⁹ Leblanc J, Côté J, Pagé MG, Piquet H, Simon T, Crémieux AC; DICI-VIH (Dépistage Infirmier Ciblé du VIH) Group. Implementation of Nurse-Driven HIV Screening Targeting Key Populations in Emergency Departments: A Multilevel Analysis From the DICI-VIH Trial. *Worldviews Evid Based Nurs* 2019 Dec;16(6):444-453. doi: 10.1111/wvn.12393. Epub 2019 Sep 2.
- ⁷⁰ Hoot NR, Aronsky D. Systematic review of emergency department crowding: causes, effects, and solutions. *Ann Emerg Med*. 2008 Aug;52(2):126-36. doi: 10.1016/j.annemergmed.2008.03.014. Epub 2008 Apr 23. PMID: 18433933; PMCID: PMC7340358.

-
- ⁷¹ Blackburn J, Ousey K, Goodwin E. Information and communication in the emergency department. *Int Emerg Nurs*. 2019 Jan;42:30-35. doi: 10.1016/j.ienj.2018.07.002. Epub 2018 Aug 17. PMID: 30122462.
- ⁷² McRae AD, Perry JJ, Brehaut J, Brown E, Curran J, Emond M, Hohl C, Taljaard M, Stiell IG. Engaging emergency clinicians in emergency department clinical research. *CJEM*. 2018 May;20(3):443-447. doi: 10.1017/cem.2017.434. Epub 2018 Jan 30. PMID: 29378670.
- ⁷³ Babl FE, Curtis N, Dalziel SR. Review article: A primer for clinical researchers in the emergency department: Part VII. Considering a research higher degree in emergency medicine: How does it work, where to start, what to consider. *Emerg Med Australas*. 2019 Feb;31(1):4-10. doi: 10.1111/1742-6723.13213. Epub 2018 Dec 11. PMID: 30548155.
- ⁷⁴ Smith MK, Rutstein SE, Powers KA, Fidler S, Miller WC, Eron JJ Jr, Cohen MS. The detection and management of early HIV infection: a clinical and public health emergency. *J Acquir Immune Defic Syndr*. 2013 Jul;63 Suppl 2(0 2):S187-99. doi: 10.1097/QAI.0b013e31829871e0. PMID: 23764635; PMCID: PMC4015137.
- ⁷⁵ Rutstein SE, Ananworanich J, Fidler S, Johnson C, Sanders EJ, Sued O, Saez-Cirion A, Pilcher CD, Fraser C, Cohen MS, Vitoria M, Doherty M, Tucker JD. Clinical and public health implications of acute and early HIV detection and treatment: a scoping review. *J Int AIDS Soc*. 2017 Jun 28;20(1):21579. doi: 10.7448/IAS.20.1.21579. PMID: 28691435; PMCID: PMC5515019.
- ⁷⁶ Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. *New England Journal of Medicine* 2005;352(February (6)):570–85.
- ⁷⁷ Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1: Rakai Project Study Group. *New England Journal of Medicine* 2000;342(March (13)):921–9, 30.
- ⁷⁸ Kroon EDMB, Phanuphak N, Shattock AJ, Fletcher JLK, Pinyakorn S, Chomchey N, Akapirat S, de Souza MS, Robb ML, Kim JH, van Griensven F, Ananworanich J, Wilson DP. Acute HIV infection detection and immediate treatment estimated to reduce transmission by 89% among men who have sex with men in Bangkok. *J Int AIDS Soc*. 2017 Jun 28;20(1):21708. doi: 10.7448/IAS.20.1.21708. PMID: 28691441; PMCID: PMC5515043.
- ⁷⁹ Miller WC, Rosenberg NE, Rutstein SE, Powers KA. Role of acute and early HIV infection in the sexual transmission of HIV. *Curr Opin HIV AIDS*. 2010 Jul;5(4):277-82. doi: 10.1097/COH.0b013e32833a0d3a. PMID: 20543601; PMCID: PMC3130067.
- ⁸⁰ Bell S, Adamson J, Martin F, Doran T. HIV testing amongst older sexual health clinic attendees in England: an epidemiological study. *Int J STD AIDS*. 2019 Feb;30(2):113-119. doi: 10.1177/0956462418796445. Epub 2018 Sep 19. PMID: 30231832.
- ⁸¹ Campos-Outcalt D, Mickey T, Weisbuch J, Jones R. Integrating routine HIV testing into a public health STD clinic. *Public Health Rep*. 2006 Mar-Apr;121(2):175-80. doi: 10.1177/003335490612100212. PMID: 16528951; PMCID: PMC1525258.
- ⁸² Hamill *et al.* (2007) Time to move towards opt-out testing for HIV in the UK. *British Medical Journal*. Vol. 334. pp.1352-1354.
- ⁸³ Public Health England: Future Commissioning of London HIV Prevention Services Project Steering Group. Review of HIV epidemiology in London (<https://www.londoncouncils.gov.uk/node/28465>)
- ⁸⁴ Bundle Nick, Balasegaram Sooria, Parry Sarah, Ullah Sadna, Harris Ross J, Ahmad Karim, Foster Graham R, Tong Cheuk YW, Orkin Chloe. Seroprevalence and demographic factors associated with hepatitis B, hepatitis C and HIV infection

from a hospital emergency department testing programme, London, United Kingdom, 2015 to 2016. *Euro Surveill.* 2019;24(27):pii=1800377

⁸⁵ Cieply L et al (2019). Seroprevalence of HCV, HBV and HIV in two inner-city London emergency departments. *Epidemiology and Infection* 147, e145, 1–14

⁸⁶ Hempling MC, Zielicka-Hardy A, Ellis JP, Majewska W, Fida G. Routine HIV testing in the Emergency Department: feasible and acceptable? *Int J STD AIDS.* 2016 Dec;27(14):1267-1274. doi: 10.1177/0956462415613727. Epub 2015 Oct 25. PMID: 26503556.

⁸⁷ Parry S, Bundle N, Ullah S, Foster GR, Ahmad K, Tong CYW, Balasegaram S, Orkin C. Implementing routine blood-borne virus testing for HCV, HBV and HIV at a London Emergency Department - uncovering the iceberg? *Epidemiol Infect.* 2018 Jun;146(8):1026-1035. doi: 10.1017/S0950268818000870. Epub 2018 Apr 17. PMID: 29661260.

⁸⁸ Bradshaw D, Rae C, Rayment M, Turner N, Turner R, Pickard G, Pillay K, Roberts P, Foxton M, Sullivan AK. HIV/HCV/HBV testing in the emergency department: a feasibility and seroprevalence study. *HIV Med.* 2018 Feb;19 Suppl 1:52-57. doi: 10.1111/hiv.12590. PMID: 29488696.

⁸⁹ Bath R, Ahmad K, Orkin C. Routine HIV testing within the emergency department of a major trauma centre: a pilot study. *HIV Med.* 2015 May;16(5):326-8. doi: 10.1111/hiv.12216. Epub 2015 Jan 21. PMID: 25604553.

⁹⁰ Orkin C, Flanagan S, Wallis E, Ireland G, Dhairyawan R, Fox J, Nandwani R, O'Connell R, Lascar M, Bulman J, Reeves I, Palfreeman A, Foster GR, Ahmad K, Anderson J, Tong CY, Lattimore S. Incorporating HIV/hepatitis B virus/hepatitis C virus combined testing into routine blood tests in nine UK Emergency Departments: the "Going Viral" campaign. *HIV Med.* 2016 Mar;17(3):222-30. doi: 10.1111/hiv.12364. PMID: 26919291.

⁹¹ Dhairyawan R, O'Connell R, Flanagan S, Wallis E, Orkin C. Linkage to care after routine HIV, hepatitis B & C testing in the emergency department: the 'Going Viral' campaign. *Sex Transm Infect.* 2016 Nov;92(7):557. doi: 10.1136/sextrans-2016-052742. PMID: 30208368.

⁹² Hopkins MJ, Todd S, Beadsworth M, Anderson C, Mohamed Z, Muir D, Vivancos R, Brown AS, Ruf M, Chawla A. Consistent high prevalence of undiagnosed blood-borne virus infection in patients attending large urban emergency departments in England. *J Viral Hepat.* 2020 Jan;27(1):88-91. doi: 10.1111/jvh.13197. Epub 2019 Oct 1. PMID: 31448490; PMCID: PMC6972612.

⁹³ Kecojevic A, Lindsell CJ, Lyons MS, et al. Public Health and Clinical Impact of Increasing Emergency Department-Based HIV Testing: Perspectives From the 2007 Conference of the National Emergency Department HIV Testing Consortium. *Ann Emerg Med.* Jul; 2011 58(Suppl 1):S151–S159. e151. [PubMed: 21684395]

⁹⁴ Irvin, Flagel; Fox. The Emergency Department is Not the Ideal Place for Routine HIV Testing. *Ann Emerg Med.* 2007; 49(5):722–722. [PubMed: 17452276]

⁹⁵ Kelen GD. Public Health Initiatives in the Emergency Department: Not So Good for the Public Health? *Academic Emergency Medicine.* 2008; 15(2):194–197. [PubMed: 18275451]

⁹⁶ Rayment M, Rae C, Ghooloo F, Doku E, Hardie J, Finlay S, Gidwani S, Atkins M, Roberts P, Sullivan AK. Routine HIV testing in the emergency department: tough lessons in sustainability. *HIV Med.* 2013 Oct;14 Suppl 3:6-9. doi: 10.1111/hiv.12069. PMID: 24033895.

⁹⁷ d'Almeida KW, Kierzek G, de Truchis P, Le Vu S, Pateron D, Renaud B, Semaille C, Bousquet V, Simon F, Guillemot D, Lert F, Crémieux AC; Emergency Department HIV-Screening Group. Modest public health impact of nontargeted human

immunodeficiency virus screening in 29 emergency departments. *Arch Intern Med*. 2012 Jan 9;172(1):12-20. doi: 10.1001/archinternmed.2011.535. Epub 2011 Oct 24. PMID: 22025095.

⁹⁸ Haukoos JS. The Impact of Nontargeted HIV Screening in Emergency Departments and the Ongoing Need for Targeted Strategies: Comment on “Modest Public Health Impact of Nontargeted Human Immunodeficiency Virus Screening in 29 Emergency Departments”. *Arch Intern Med*. 2012;172(1):20–22. doi:10.1001/archinternmed.2011.538

⁹⁹ Cristina Gómez-Ayerbe et al. Impact of a structured HIV testing program in a hospital emergency department and a primary care center. *PLOS ONE* | <https://doi.org/10.1371/journal.pone.0220375> August 1, 2019

¹⁰⁰ Hudepohl NJ, Lindsell CJ, Hart KW et al. Effect of an emergency department HIV testing program on the proportion of emergency department patients who have been tested. *Ann Emerg Med* 2011; 58:S140–4.